In another sign of the growing clout nonprofits have in the drug research field, the Cystic Fibrosis Foundation is stepping up with a $58 million commitment to back Pfizer's work on a new therapy aimed at the most common target of the lethal lung disease.
After considering the trial's failure to meet its co-primary endpoints and questioning the data gathered at 8 sites, the agency is recommending that the experts gathering to discuss the drug's fate on Thursday reject the therapy.
The FDA has given pharma giant Pfizer ($PFE) a fast-track review of its drug tafamidis meglumine for treating the rare disease known as transthyretin familial amyloid polyneuropathy, meaning the...
Data from a Phase II/III trial of transthyretin familial amyloid polyneuropathy (TTR-FAP) showed that Pfizer and FoldRx's drug tafamidis slowed disease progression over 30 months. No safety concerns
With a new neurodegenerative disease therapy up for regulatory review and a fresh $29 million financing round sitting in the bank, FoldRx announced this morning that Pfizer has moved in to scoop up
Cambridge, MA-based FoldRx has rounded up $29 million in new funding, with new investors Novo Ventures and Morgenthaler Ventures joining Healthcare Ventures, Fidelity Biosciences, TPG Biotechnology,
FoldRx Pharmaceuticals announced that the Phase II/III study for tafamidis demonstrates that the drug "significantly halts disease progression for patients with a disease called